Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Federal Trade Commission
Cipla
Cantor Fitzgerald
Moodys
Dow
US Department of Justice
Chinese Patent Office
Citi

Generated: May 26, 2018

DrugPatentWatch Database Preview

EPANOVA Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Summary for EPANOVA
International Patents:85
US Patents:8
Applicants:1
NDAs:1
Bulk Api Vendors: 1
Clinical Trials: 15
Patent Applications: 1
Formulation / Manufacturing:see details
DailyMed Link:EPANOVA at DailyMed
Drug patent expirations by year for EPANOVA
Synonyms for EPANOVA
Anti-hypertriglycemic (oral/capsule, hypertriglyceridemia/crohn's disease), Omthera
D0G7WY
F005100000
Fatty Acids, Omega-3
n-3 Polyunsaturated Fatty Acid
n-3 PUFA
n-3 PUFAs
Omefas
Omega-3 Fatty Acids
Omega-3 Polyunsaturates
Polyunsaturated Fatty Acids (PUFAs)
QPEOIOLHJXXJFN-GNGJDXFDSA-N

US Patents and Regulatory Information for EPANOVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for EPANOVA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,729,321 Autonomous private key recovery ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Accenture
US Department of Justice
McKinsey
Cantor Fitzgerald
UBS
Cipla
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.